TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination…
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5…
PR Newswire is a distributor of press releases headquartered in New York City.